Streptococcus viridans group

Antibiotic
% Susceptible
2010
% Susceptible
2012
% Susceptible
2014
% Susceptible
2016
% Susceptible
2018
Ampicillin
90
 89 85 94 83
Azithromycin
-*
 59
64
 65 44
Aztreonam
-*
 -*
-*
 -* -*
Cefazolin
96
 +
+
+ +
Cefepime
+
 97
+
98 92
Ceftazidime
+/-
 +/-
+/-
 +/- +/-
Ceftriaxone
96
 97
95
 98 96
Cefuroxime
+
 98
+
+ +
Ciprofloxacin
+-*
 +-*
+-*
 +-* +-*
Clarithromycin
+-*
 +-*
+-*
 +-* +-*
Clindamycin
89
 88
93
 88 72
Doxycycline
+
 70
70
 78 58
Erythromycin
60
 54
63
 62 39
Gentamicin
-*
 -*
-*
 -* -*
Imipenem
+
 +
+
 + +
Levofloxacin 96 90 92 91 96
Meropenem + 99 + 95 94
Moxifloxacin + + + + +
Nitrofurantoin & & & & &
Oxacillin/Naf +- +- +- +- +-
Penicillin 89 90 84 92 88
Piperacillin + + + + +
Piperacillin/tazo + + + + +
Ticarcillin/Clav + + + + +
Tobramycin -* -* -* -* -*
TMP/SMX 72 72 72 + +
Unasyn/Aug + + + + +
Vancomycin 99 100 100 100 100
       
# Tested 115 143 144 87 52

Comments:  

 

Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections